|
|
Volumn 2, Issue 7, 2006, Pages 366-367
|
|
What is the effect of fenofibrate on cardiovascular disease events in patients with type 2 diabetes? Commentary
|
|
Author keywords
Cardiovascular events; Fenofibrate; Lipids; Type 2 diabetes
|
|
Indexed keywords
ANTILIPEMIC AGENT;
CHOLESTEROL;
FENOFIBRATE;
HIGH DENSITY LIPOPROTEIN CHOLESTEROL;
PLACEBO;
TRIACYLGLYCEROL;
ADULT;
ALBUMIN BLOOD LEVEL;
AUSTRALIA;
CARDIOVASCULAR DISEASE;
CHOLESTEROL BLOOD LEVEL;
CHRONIC LIVER DISEASE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DEEP VEIN THROMBOSIS;
DIET;
DRUG TOLERABILITY;
FEMALE;
FINLAND;
GALLBLADDER DISEASE;
HEART DEATH;
HEART INFARCTION;
HUMAN;
ISCHEMIC HEART DISEASE;
KIDNEY DISEASE;
LUNG EMBOLISM;
MAJOR CLINICAL STUDY;
MALE;
MORTALITY;
MULTICENTER STUDY;
NEW ZEALAND;
NON INSULIN DEPENDENT DIABETES MELLITUS;
NOTE;
PANCREATITIS;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL;
RETINOPATHY;
REVASCULARIZATION;
RISK REDUCTION;
TRIACYLGLYCEROL BLOOD LEVEL;
WORLD HEALTH ORGANIZATION;
|
|
EID: 33745893208
PISSN: 17458366
EISSN: 17458374
Source Type: Journal
DOI: 10.1038/ncpendmet0200 Document Type: Note |
|
Times cited : (1)
|
|
References (4)
|
